Director, US Real-World Evidence and Health Outcomes – Oncology Pipeline

GSK•Durham, NC

1d•Hybrid

About The Position

This Director role supports the US Pipeline Oncology Director in leading US RWE & HO strategy and execution for Oncology pipeline assets. The role is accountable for developing and delivering components of the US data generation plan (including RWE and economic value evidence), ensuring strategic alignment across key internal stakeholders (US Medical, Commercial/Market Access, Global RWE & HO, Global Medical Affairs, R&D Epidemiology and Clinical Development), and driving high-quality deliverables that inform internal decision-making during product development, pre-launch readiness, and lifecycle planning. The role is anchored to 1–2 priority pipeline assets/indications, with backup support across the broader Oncology pipeline portfolio as needed. Approximately 20% of the role will support RWE & HO needs for a marketed Oncology product in endometrial and rectal cancer, aligned to lifecycle and customer evidence priorities.

Requirements

Master’s degree or PhD in health economics and outcomes research, epidemiology, public health, biostatistics, or related discipline.
3+ years’ experience within the pharmaceutical industry or academia related research within US Oncology experience.
Designing a publication plan and having a presence of HEOR research studies at major clinical congresses.
Experience managing multiple projects simultaneously.
Expertise in HEOR and economic evaluation study designs/methods evidenced by publications and/or contributing to study concept sheets and protocols (including clear research questions, endpoints, data source selection, and bias/confounding mitigation), reviewing/authoring key sections of statistical analysis plans and study reports, and ensuring publication/disclosure readiness in accordance with internal SOPs and external requirements.
Strong communication and presentation skills, demonstrated by developing and presenting clear, decision-oriented materials (e.g., evidence strategy slides, executive readouts) and summarizing outcomes/next steps for senior audiences.
Proven ability to prioritize, pivot, and manage multiple projects simultaneously in a matrix environment.

Nice To Haves

Demonstrated success developing and executing health outcomes research plans and delivering high-quality data generation outputs.
Oncology experience (US or global), including familiarity with evolving standards of care, evidence requirements, and stakeholder needs across disease areas.
Masters + ~4–6 years or PhD with 2–4+ years of experience within the pharmaceutical industry and/or managed care, hospital, academic, or healthcare consulting environment, including experience collaborating with field-facing teams (e.g., Field Based Payer Medical, Field Medical) and/or Market Access partners.
Experience managing real-world data sources and vendors (e.g., claims, EHR, registries) and translating findings into actionable insights and value messages.
Demonstrated ability to influence without authority in a matrix environment, evidenced by aligning cross-functional stakeholders on objectives/trade-offs, documenting decisions, and driving actions to closure.
Strategic execution experience, demonstrated by translating evidence strategy into workplans (milestones, timelines, resourcing) and delivering outputs across 1–2 concurrent asset workstreams.
Demonstrated project and vendor management experience, including defining scope and success criteria, tracking budgets/timelines, proactively identifying risks/issues, and implementing mitigation plans through change control.
Experience contributing to congress strategy and publication planning (abstracts, posters, manuscripts).

Responsibilities

Implementation of RWE/HO research by developing evidence generation plan and designing studies for 1–2 priority pipeline assets/indications, aligned to US medical, payer, and access needs; translate strategy into actionable workplans, timelines, and resourcing proposals. Provide backup portfolio support for other pipeline assets as needed.
Own day-to-day leadership for assigned real-world evidence and health outcomes studies (e.g., real-world evidence studies, cost-effectiveness/budget impact analyses, burden of illness, treatment patterns, patient-focused outcomes) including design and execution in partnership with internal functions and external vendors.
Support the US Pipeline Oncology Director in running cross-functional evidence strategy forums and asset-specific meetings by developing agendas/materials, surfacing options, documenting decisions, and tracking actions to closure.
Draft/review project specifications, protocols, statistical analysis plans, study reports, abstracts, posters, and manuscripts; ensure adherence to SOPs and high scientific/operational quality.
Provide feedback to Clinical Development and cross-functional teams on optimal trial design to ensure enrollment of US-relevant patient populations and collection of endpoints/outcomes that support US stakeholder needs (e.g., health-related quality of life, patient-reported outcomes, resource utilization, and other health outcomes measures).
Provide RWE & HO input to internal decision-making during development and commercialization planning (e.g., trial design considerations, data gap assessments, value messages, evidence prioritization and sequencing).
Contribute ~20% effort to US RWE & HO strategy and execution for a marketed product in endometrial and rectal cancer, including data generation planning, cross-functional alignment, and delivery of analyses/publications that support lifecycle evidence needs and value communication.
Maintain strong alignment with Field Based Payer Medical Teams and other field stakeholders to obtain customer insights; incorporate insights into evidence plans and value communication needs.
Manage vendors and contractors for assigned studies, including scope, timelines, budget tracking, and change control; escalate risks/issues proactively.
Complete required training, adhere to company/department SOPs, and contribute to continuous improvement of processes that enable efficient planning, execution, and dissemination of RWE & HO deliverables.